Literature DB >> 17671763

The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis.

Haiyan Jin1, Shuji Terai, Isao Sakaida.   

Abstract

BACKGROUND: Hepatic stellate cells (HSCs) play a pivotal role in liver fibrogenesis. Here, we studied whether the iron chelator deferoxamine (DFO) affected cultured HSC activation and apoptosis.
METHODS: The effect of DFO on HSCs was investigated using quiescent and activated stellate cells.
RESULTS: Treatment with DFO inhibited HSC activation, resulting in the reduced expression of alpha-smooth muscle actin protein and type I procollagen, matrix metalloproteinase-2 and -9, and tissue inhibitors of metalloproteinase-1 and -2 mRNAs. DFO induced apoptosis of activated HSCs, which was associated with decreasing Bcl-2 expression and the release of cytochrome c from the mitochondria to the cytosol with enhanced caspase-3 activity. DFO also induced activated HSCs to express peroxisome proliferator-activated receptor gamma with the reaccumulation of intracellular lipids.
CONCLUSIONS: The iron chelation of stellate cells inhibits their activation, causing them to become deactivated as well as to undergo apoptosis. These data suggest a potential role for an iron chelation treatment of liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17671763     DOI: 10.1007/s00535-007-2020-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

1.  Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.

Authors:  T Knittel; M Mehde; A Grundmann; B Saile; J G Scharf; G Ramadori
Journal:  Histochem Cell Biol       Date:  2000-06       Impact factor: 4.304

2.  Cellular uptake and release of two contrasting iron chelators.

Authors:  H Cable; J B Lloyd
Journal:  J Pharm Pharmacol       Date:  1999-02       Impact factor: 3.765

Review 3.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

4.  Identification and characterization of the hepatic stellate cell transferrin receptor.

Authors:  Kim R Bridle; Darrell H G Crawford; Grant A Ramm
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 5.  Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis.

Authors:  M J Arthur
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-08       Impact factor: 4.052

6.  Protection against acetaminophen-induced liver injury in vivo by an iron chelator, deferoxamine.

Authors:  I Sakaida; K Kayano; S Wasaki; A Nagatomi; Y Matsumura; K Okita
Journal:  Scand J Gastroenterol       Date:  1995-01       Impact factor: 2.423

7.  Fibrosis accelerates the development of enzyme-altered lesions in the rat liver.

Authors:  I Sakaida; K Hironaka; K Uchida; C Suzuki; K Kayano; K Okita
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

8.  The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.

Authors:  D Richardson; P Ponka; E Baker
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

9.  Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.

Authors:  A E Kossakowska; D R Edwards; S S Lee; L S Urbanski; A L Stabbler; C L Zhang; B W Phillips; Y Zhang; S J Urbanski
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Iron at the cell surface controls DNA synthesis in CCl 39 cells.

Authors:  F J Alcain; H Löw; F L Crane
Journal:  Biochem Biophys Res Commun       Date:  1994-08-30       Impact factor: 3.575

View more
  9 in total

1.  Natural taurine promotes apoptosis of human hepatic stellate cells in proteomics analysis.

Authors:  Xin Deng; Jian Liang; Zhi-Xiu Lin; Fa-Sheng Wu; Ya-Ping Zhang; Zhi-Wei Zhang
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

2.  Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation.

Authors:  Paolo Santambrogio; Benedetta Gaia Erba; Alessandro Campanella; Anna Cozzi; Vincenza Causarano; Laura Cremonesi; Anna Gallì; Matteo Giovanni Della Porta; Rosangela Invernizzi; Sonia Levi
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

3.  Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments.

Authors:  Takahiro Yamasaki; Issei Saeki; Isao Sakaida
Journal:  Hepatol Int       Date:  2014-01-29       Impact factor: 6.047

Review 4.  Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.

Authors:  Taro Takami; Takahiro Yamasaki; Issei Saeki; Toshihiko Matsumoto; Yutaka Suehiro; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

5.  Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines.

Authors:  Jiabin Yang; Yumin Xia; Xiaoming Liu; Shan Jiang; Layuan Xiong
Journal:  Lasers Med Sci       Date:  2009-08-25       Impact factor: 3.161

Review 6.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

7.  Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.

Authors:  Issei Saeki; Naoki Yamamoto; Takahiro Yamasaki; Taro Takami; Masaki Maeda; Koichi Fujisawa; Takuya Iwamoto; Toshihiko Matsumoto; Isao Hidaka; Tsuyoshi Ishikawa; Koichi Uchida; Kenji Tani; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

8.  Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib.

Authors:  Naoki Yamamoto; Takahiro Yamasaki; Taro Takami; Koichi Uchida; Koichi Fujisawa; Toshihiko Matsumoto; Issei Saeki; Shuji Terai; Isao Sakaida
Journal:  J Clin Biochem Nutr       Date:  2016-03-15       Impact factor: 3.114

Review 9.  Iron-Induced Liver Injury: A Critical Reappraisal.

Authors:  Steven A Bloomer; Kyle E Brown
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.